Skip to content

Author

H. Schunkert

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Risk of restenosis for in-stent restenosis and de novo lesions treated during the same percutaneous coronary intervention procedure

Patients undergoing percutaneous coronary intervention (PCI) for in-stent restenosis (ISR) lesions have been reported to experience worse outcomes than those treated for de novo lesions. However, no study has yet directly compared these two lesion types when treated in the same patient during the same procedure....

D. Lahu, S. Lahu, F. Simonetti et al. · 0 citations
Open access Oct 2026

TMEM106B alters vascular smooth muscle cell phenotypes and lysosomal function leading to atherosclerosis

Atherosclerotic cardiovascular diseases (ASCVD), including coronary artery disease (CAD), peripheral artery disease (PAD), and ischemic stroke (IS), account for the majority of global cardiovascular mortality. Although they affect distinct vascular territories, these conditions share overlapping traditional and g...

C. Abrahamian, L. Li, M. Ajayan et al. · 0 citations
Open access Oct 2026

The impact of multiple stent layers on the 10-year outcomes of patients treated with percutaneous coronary intervention for in-stent restenosis

In patients undergoing PCI for ISR, lesions with 2 or more stent layers were associated with a higher risk of recurrent revascularisation than single-layer lesions, however, patients in the multilayer group did not have a higher risk of cardiac death or myocardial infarction.

D. Lahu, T. Koch, V. Schmidt et al. · 0 citations
Open access Oct 2026

Real-world efficacy and tolerability of lipid-lowering therapy in children with monogenic familial hypercholesterolemia in primary care

Familial hypercholesterolaemia (FH) is characterised by elevated LDL-C levels from an early age and confers a high risk of premature cardiovascular disease. Although guidelines recommend the early initiation of lipid-lowering medication (LLM) following an FH diagnosis, there is limited data on the uptake, effecti...

R. Schmieder, J. Krefting, S. Arens et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.